Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: Comparison of formulations and administration routes of vaccines

Vaccine

Volumn 27, Issue 52, 2009, Pages 7402-7408

  Kashima, Yoshitaka ^a   Ikeda, Mizuho ^a   Itoh, Yasushi ^a   Sakoda, Yoshihiro ^b   Nagata, Tomoya ^a   Miyake, Taichiro ^a   Soda, Kosuke ^b   Ozaki, Hiroichi ^d   Nakayama, Misako ^a   Shibuya, Hitomi ^b   Okamatsu, Masatoshi ^b   Ishigaki, Hirohito ^a   Ishida, Hideaki ^a   Sawai, Toshihiro ^a   Kawaoka, Yoshihiro ^e,f   Kida, Hiroshi ^b,c   Ogasawara, Kazumasa ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e THE UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

H5N1; Live vaccine; Non pathogenic influenza virus library

Indexed keywords

AVIAN H5N1 INFLUENZA VIRUS LIVE VACCINE; AVIAN H5N1 INFLUENZA VIRUS WHOLE PARTICLE VACCINE; INFLUENZA VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AVIAN H5N1 INFLUENZA VIRUS INFECTION; AVIAN INFLUENZA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS VIRULENCE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CELLS, CULTURED; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED;

EID: 70649093873     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.089     Document Type: Article

References (42)

1. Gambotto A., Barratt-Boyes S.M., de Jong M.D., Neumann G., and Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371 9622 (2008) 1464-1475
2. Wang H., Feng Z., Shu Y., Yu H., Zhou L., Zu R., et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 371 9622 (2008) 1427-1434
3. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363 9415 (2004) 1099-1103
4. Horimoto T., and Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med 12 11 (2006) 506-514
5. Johnson Jr. P.R., Feldman S., Thompson J.M., Mahoney J.D., and Wright P.F. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 17 4 (1985) 325-335
6. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15 1 (2009) 34-41
7. Rauh L.W., and Schmidt R. Measles Immunization with Killed Virus Vaccine. Serum antibody titers and experience with exposure to measles epidemic. Am J Dis Child 109 (1965) 232-237
8. Fulginiti V.A., Eller J.J., Downie A.W., and Kempe C.H. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202 12 (1967) 1075-1080
9. Wareing M.D., and Tannock G.A. Live attenuated vaccines against influenza; an historical review. Vaccine 19 25-26 (2001) 3320-3330
10. Clements M.L., Makhene M.K., Karron R.A., Murphy B.R., Steinhoff M.C., Subbarao K., et al. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center. J Infect Dis 173 1 (1996) 44-51
11. Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., and Bridges C.B. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 53 RR-6 (2004) 1-40
12. Jefferson T.O., Rivetti D., Di Pietrantonj C., Rivetti A., and Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2 (2007) CD001269
13. Kida H., and Sakoda Y. Library of influenza virus strains for vaccine and diagnostic use against highly pathogenic avian influenza and human pandemics. Dev Biol (Basel) 124 (2006) 69-72
14. Sawai T., Itoh Y., Ozaki H., Isoda N., Okamoto K., Kashima Y., et al. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 124 (2008) 155-165
15. Lu X., Edwards L.E., Desheva J.A., Nguyen D.C., Rekstin A., Stephenson I., et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24 44-46 (2006) 6588-6593
16. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 23 1 (1986) 73-76
17. Powers D.C., Sears S.D., Murphy B.R., Thumar B., and Clements M.L. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 27 12 (1989) 2666-2671
18. Cox R.J., Brokstad K.A., and Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59 1 (2004) 1-15
19. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., and Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25 29 (2007) 5367-5373
20. Ninomiya A., Ogasawara K., Kajino K., Takada A., and Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20 25-26 (2002) 3123-3129
21. Soda K., Sakoda Y., Isoda N., Kajihara M., Haraguchi Y., Shibuya H., et al. Development of vaccine strains of H5 and H7 influenza viruses. Jpn J Vet Res 55 2-3 (2008) 93-98
22. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 12 (2004) 1179-1188
23. Nagata T., Toyota T., Ishigaki H., Ichihashi T., Kajino K., Kashima Y., et al. Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. Vaccine 25 26 (2007) 4914-4921
24. Kida H., Brown L.E., and Webster R.G. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122 1 (1982) 38-47
25. Ozaki H., Sugiura T., Sugita S., Imagawa H., and Kida H. Detection of antibodies to the nonstructural protein (NS1) of influenza A virus allows distinction between vaccinated and infected horses. Vet Microbiol 82 2 (2001) 111-119
26. Itoh Y., Ozaki H., Tsuchiya H., Okamoto K., Torii R., Sakoda Y., et al. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26 4 (2008) 562-572
27. Lindstrom S.E., Cox N.J., and Klimov A. Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957-1972: evidence for genetic divergence and multiple reassortment events. Virology 328 1 (2004) 101-119
28. Ilyushina N.A., Rudneva I.A., Shilov A.A., Klenk H.D., and Kaverin N.V. Postreassortment changes in a model system: HA-NA adjustment in an H3N2 avian-human reassortant influenza virus. Arch Virol 150 7 (2005) 1327-1338
29. Suguitan Jr. A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3 9 (2006) e360
30. + T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 26 52 (2008) 6965-6974
31. Wright P.F., Neumann G., and Kawaoka Y. Orthomyxoviruses. Fields Virology. 5th ed. (2007), Lippincott Williams & Wilkins, a Wolters Kluwer Business, Philadelphia 1727 pp [Chapter 48]
32. Scholtissek C. Potential hazards associated with influenza virus vaccines. Dev Biol Stand 84 (1995) 55-58
33. Batten C.A., Maan S., Shaw A.E., Maan N.S., and Mertens P.P. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res 137 1 (2008) 56-63
34. Guillot L., Le Goffic R., Bloch S., Escriou N., Akira S., Chignard M., et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280 7 (2005) 5571-5580
35. Kumagai Y., Takeuchi O., Kato H., Kumar H., Matsui K., Morii E., et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 27 2 (2007) 240-252
36. Koyama S., Ishii K.J., Kumar H., Tanimoto T., Coban C., Uematsu S., et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol 179 7 (2007) 4711-4720
37. Kido H., Yokogoshi Y., Sakai K., Tashiro M., Kishino Y., Fukutomi A., et al. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 267 19 (1992) 13573-13579
38. Scheibe M., Bethge C., Witt M., and Hummel T. Intranasal administration of drugs. Arch Otolaryngol Head Neck Surg 134 6 (2008) 643-646
39. Coyne C.B., Vanhook M.K., Gambling T.M., Carson J.L., Boucher R.C., and Johnson L.G. Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 13 9 (2002) 3218-3234
40. Youakim A., and Ahdieh M. Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am J Physiol 276 5 Pt 1 (1999) G1279-G1288
41. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 7089 (2006) 101-105
42. Han J.H., Akira S., Calame K., Beutler B., Selsing E., and Imanishi-Kari T. Class switch recombination and somatic hypermutation in early mouse B cells are mediated by B cell and Toll-like receptors. Immunity 27 1 (2007) 64-75